Return to homepagePandemic Pact

Comparing Medicines for Treating Type 2 Diabetes among Patients with Chronic Kidney Disease

  • Funded by Patient-Centered Outcomes Research Institute
  • Total publications:0 publications

Grant number: unknown

Grant search

Key facts

  • Disease

    COVID-19

  • Known Financial Commitments (USD)

    $472,323

  • Funder

    Patient-Centered Outcomes Research Institute

  • Principal Investigator

    MD. Alvin Mushlin

  • Research Location

    United States of America

  • Lead Research Institution

    Joan and Sanford I. Weill Medical College of Cornell University

  • Research Priority Alignment

    N/A

  • Research Category

    Clinical characterisation and management

  • Research Subcategory

    Prognostic factors for disease severity

  • Special Interest Tags

    N/A

  • Study Type

    Clinical

  • Clinical Trial Details

    Not applicable

  • Broad Policy Alignment

    Pending

  • Age Group

    Unspecified

  • Vulnerable Population

    Unspecified

  • Occupations of Interest

    Unspecified

Abstract

Patients with type 2 diabetes and other related health problems, such as obesity or kidney disease, may have a high risk of severe COVID-19. Severe COVID-19 can lead to a hospital stay, breathing support by machine, and even death. Patients and their health providers want to know how to manage diabetes to reduce these risks. With this enhancement, the research team will look at whether people with high blood sugar have a higher risk of a hospital stay. The team will also compare rates of COVID-19 hospital stays for people who take different diabetes medicines. Results will help patients and their providers manage and treat diabetes during the pandemic.